financetom
Business
financetom
/
Business
/
Pizza Pizza Royalty Q3 adj EPS down, hurt by heightened competition
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Pizza Pizza Royalty Q3 adj EPS down, hurt by heightened competition
Nov 4, 2025 2:51 PM

Overview

* Pizza Pizza Q3 royalty pool system sales increased 2.0% yr/yr

* Adjusted EPS for Q3 decreased 1.3% yr/yr

* Restaurant network increased by 11 net locations

Outlook

* Company plans to grow traditional restaurant network by 2% to 3% in 2025

* Company investing in digital ordering and service speed to drive growth

* Future dividends expected to be funded by cash flow from operations and cash reserve

Result Drivers

* COMPETITION IMPACT - Heightened competition in the QSR sector affected customer traffic, contributing to a slight decrease in adjusted EPS

* RESTAURANT EXPANSION - 11 net new locations added in Q3, contributing to increased royalty pool system sales

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 C$0.236

Adjusted

EPS

Q3 C$5.14

Adjusted mln

Net

Income

Q3 C$7.87

Adjusted mln

Income

from

Operatio

ns

Q3 Basic C$0.231

EPS

Analyst Coverage

* The one available analyst rating on the shares is "hold"

* The average consensus recommendation for the restaurants & bars peer group is "buy."

* Wall Street's median 12-month price target for Pizza Pizza Royalty Corp ( PZRIF ) is C$17.00, about 9.4% above its November 3 closing price of C$15.41

* The stock recently traded at 16 times the next 12-month earnings vs. a P/E of 16 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
AbbVie trims annual profit forecast after expected $2.7 billion R&D hit
AbbVie trims annual profit forecast after expected $2.7 billion R&D hit
Oct 3, 2025
Oct 3 (Reuters) - Drugmaker AbbVie said on Friday it has lowered its annual profit forecast, after a flagging an expected $2.7 billion charge related to in-process research and development (IPR&D) expenses in the third quarter. Shares of the North Chicago-based company were down nearly 1% at $232.0 in extended trade. AbbVie ( ABBV ) said in a regulatory filing...
BRIEF-Intelligent Group Says Unit Has Entered Into Subscription Agreement To Invest In Fine Glory Holdings
BRIEF-Intelligent Group Says Unit Has Entered Into Subscription Agreement To Invest In Fine Glory Holdings
Oct 3, 2025
Oct 3 (Reuters) - Intelligent Group Ltd ( INTJ ): * INTELLIGENT GROUP LTD ( INTJ ): UNIT HAS ENTERED INTO SUBSCRIPTION AGREEMENT TO INVEST IN FINE GLORY HOLDINGS LTD * INTELLIGENT GROUP LTD ( INTJ ): IJL WILL ACQUIRE MINORITY STAKE IN FINE GLORY VALUED AT $20 MILLION BY SUBSCRIBING TO CLASS B NON-VOTING SHARES Source text: Further company...
AbbVie trims annual profit forecast after expected $2.7 billion R&D hit
AbbVie trims annual profit forecast after expected $2.7 billion R&D hit
Oct 3, 2025
(Reuters) -Drugmaker AbbVie said on Friday it has lowered its annual profit forecast, after a flagging an expected $2.7 billion charge related to in-process research and development (IPR&D) expenses in the third quarter. Shares of the North Chicago-based company were down nearly 1% at $232.0 in extended trade. AbbVie ( ABBV ) said in a regulatory filing that such expenses...
Arcutis Biotherapeutics Insider Sold Shares Worth $884,649, According to a Recent SEC Filing
Arcutis Biotherapeutics Insider Sold Shares Worth $884,649, According to a Recent SEC Filing
Oct 3, 2025
05:15 PM EDT, 10/03/2025 (MT Newswires) -- Todd Watanabe, Director, President and Chief Executive Officer, on October 01, 2025, sold 45,000 shares in Arcutis Biotherapeutics ( ARQT ) for $884,649. Following the Form 4 filing with the SEC, Watanabe has control over a total of 1,079,574 common shares of the company, with 846,440 shares held directly and 233,134 controlled indirectly....
Copyright 2023-2026 - www.financetom.com All Rights Reserved